Summit Therapeutics Inc. Common Stock (SMMT)
Stock · NASDAQ · Health Care
$14.65as of 10/16/2026
Price chart
Active signals
SMMT Signal Track Record
How signals performed across all stocks →What SMMT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -0.1% | 50% | September 18, 2026 |
| Bollinger Band BreakdownActive now | 22 | +13.6% | 68% | July 28, 2026 |
| Bollinger Band Breakout | 23 | -1.1% | 48% | September 3, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -1.7% | 45% | September 23, 2026 |
| Any 20-session window (baseline) | +1.1% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 265
- Website
- www.smmttx.com/
Fundamentals
- 1-day range
- $14.56$15.4
- Market cap
- $10.80B
- P/E (trailing)
- —
- P/E (forward)
- -12.50
- EPS (trailing)
- $-1.12
- Dividend yield
- —
- Beta
- -1.67
- Avg. volume
- 6.00M
How Summit Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2022 annual results
Source: 10-K filed Mar 9, 2023 · via SEC EDGAR / Finnhub
Forecasts
13 analyst ratings
Summit Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SMMTSummit Therapeutics Inc. Common Stock$14.63▼ 4.81%Market cap $10.80BP/E —$12.07$29.23
- AXSMAxsome Therapeutics Inc. Common Stock$157.14▼ 2.87%Market cap $10.81BP/E —$120.12$260.19
- ABVXAbivax SA American Depositary Shares$88.13▼ 4.60%Market cap $11.19BP/E —$60.45$139
- PRAXPraxis Precision Medicines Inc. Common Stock$241.76▼ 2.61%Market cap $10.32BP/E —$50.56$392.7
- CYTKCytokinetics Incorporated Common Stock$61.95▼ 3.08%Market cap $10.13BP/E —$54.3$88.31
- RDYDr. Reddy's Laboratories Ltd Common Stock$13.07▲ 1.32%Market cap $10.11BP/E 31.61$1,101$1,415
- CORTCorcept Therapeutics Incorporated Common Stock$110.16▼ 2.83%Market cap $11.67BP/E 225.11$28.66$126.38
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SMMT Summit Therapeutics Inc. Common Stock | $10.80B | — | $14.63 | ▼ 4.81% | $12.07$29.23 |
| AXSM Axsome Therapeutics Inc. Common Stock | $10.81B | — | $157.14 | ▼ 2.87% | $120.12$260.19 |
| ABVX Abivax SA American Depositary Shares | $11.19B | — | $88.13 | ▼ 4.60% | $60.45$139 |
| PRAX Praxis Precision Medicines Inc. Common Stock | $10.32B | — | $241.76 | ▼ 2.61% | $50.56$392.7 |
| CYTK Cytokinetics Incorporated Common Stock | $10.13B | — | $61.95 | ▼ 3.08% | $54.3$88.31 |
| RDY Dr. Reddy's Laboratories Ltd Common Stock | $10.11B | 31.61 | $13.07 | ▲ 1.32% | $1,101$1,415 |
| CORT Corcept Therapeutics Incorporated Common Stock | $11.67B | 225.11 | $110.16 | ▼ 2.83% | $28.66$126.38 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Stock Market Today: S&P 500, Russell 2000 Fall as 30-Year Yield Hits 5.7%Benzinga · 10/7/2026
- Goldman Sachs Says China Biotech Is Where Big Pharma Is Shopping NowYahoo · 10/7/2026
- AstraZeneca CEO Pascal Soriot on Summit ivonescimab combosYahoo · 10/6/2026
- Amazon, Alphabet, Tesla Stock Rises: Robinhood Traders Sell AnywayBenzinga · 10/5/2026
- SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway CombosYahoo · 10/5/2026
- Summit Therapeutics Announces Closing Of AstraZeneca's $2B Convertible Preferred Investment, Equivalent To $18.36/Share Of Common Stockbenzinga · 10/5/2026
- AstraZeneca Completes $2 Billion Equity Investment in Summit TherapeuticsYahoo · 10/5/2026
- 5 British Blue Chips For Your PortfolioBenzinga · 10/5/2026
- BioNTech SE: Moving Past CovidSeekingAlpha · 10/4/2026
Insider Activity
Insider Actions →- Zanganeh Mahkam · June 12, 2026 · Buy3.81M @ $13.12
- Robert W. Duggan · June 12, 2026 · Buy3.81M @ $13.12
- Zanganeh Mahkam · June 4, 2026 · Buy100.0K @ $14.6
- Robert W. Duggan · June 4, 2026 · Buy100.0K @ $14.6
- Manmeet Singh Soni · June 4, 2026 · Buy25.0K @ $14.46
Institutional Ownership
March 31, 2026
- Total shares held
- 116.32M
- Total value held
- $2.04B
- Institutional holders
- 221
- Unknown36.39M
- Unknown10.85M
- Unknown9.65M
- Unknown8.28M
- Unknown7.03M
- Unknown5.71M
- Unknown3.70M
- Unknown3.32M
- Unknown2.41M
- Unknown2.24M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Summit Therapeutics Partners With AstraZeneca and Daiichi Sankyo
Summit Therapeutics announced a new collaboration with AstraZeneca and Daiichi Sankyo to test a cancer therapy combination. This partnership involves an ADC-bispecific approach and was described by the CEO as an important expansion of the company’s work. The stock rose 7.3% following the news, reflecting investor interest in this strategic alliance.
Summit Therapeutics Partners With AstraZeneca and Daiichi Sankyo. Summit Therapeutics announced a new collaboration with AstraZeneca and Daiichi Sankyo to test a cancer therapy combination. This partnership involves an ADC-bispecific approach and was described by the CEO as an important expansion of the company’s work. The stock rose 7.3% following the news, reflecting investor interest in this strategic alliance.